Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

22d ago, source: Stockhouse

March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients ...

Aerovate Therapeutics Inc AVTE

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Aerovate Therapeutics Inc (AVTE) Stock: Analyzing the Market Value

8d ago, source: newsheater

In conclusion, Aerovate Therapeutics Inc (AVTE) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s ...

Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ...

26d ago, source: Yahoo Finance

Aerovate Therapeutics Inc (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that improve the treatment of severe cardiopulmonary diseases, has reported an ...

Aerovate Therapeutics Stock (NASDAQ:AVTE), Analyst Ratings, Price Targets, Predictions

22d ago, source: Benzinga.com

Aerovate Therapeutics Inc has a consensus price target of $30.86, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from Wells Fargo, Jefferies ...

Aerovate Therapeutics: Poised for Market Capitalization Growth on IMPAHCT Trial Success

15d ago, source: Business Insider

Analyst Tiago Fauth of Wells Fargo maintained a Buy rating on Aerovate Therapeutics (AVTE – Research Report), retaining the price target of $35.00. Tiago Fauth’s rating is based on a thorough ...

TNGX Tango Therapeutics, Inc.

11h ago, source: Seeking Alpha

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein ...

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

22d ago, source: Yahoo Finance

March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of ...

Aerovate Therapeutics Inc (AVTE)

3d ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Aerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

21d ago, source: Finanznachrichten

March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of ...

Aerovate Therapeutics Inc (AVTE)

8d ago, source: Investing

In a recent move at Aerovate Therapeutics, Inc. (NASDAQ:AVTE), Chief Technical Officer Marinus (NASDAQ:MRNS) Verwijs has sold a significant amount of company stock. According to ...